A Phase 3, Randomized, Observer-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
|Effective start/end date||7/22/21 → 6/30/26|
- MODERNATX, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.